SCN1A and epilepsy: Finally, throughout the more than 1,200 genes that may be linked to epilepsy-related phenotypes according to the OMIM compendium, just a few tens of them can benefit from further etiopathology-guided therapeutic approaches, being their ultimate representation the ongoing antisense oligonucleotide trials for patients with Dravet syndrome related to specific SCN1A variants, and other new advanced small molecules and gene therapies in the horizon for this and other genetic etiologies in the near future (86).